MDMA-assisted therapy (MDMA-AT) for PTSD sparked debate, primarily focused on concerns of safety and efficacy. But no matter how novel a treatment may be, if it is inaccessible to the millions of people who need it, its relevance becomes insignificant.
The post Breaking Barriers: Why Accessibility Matters in PTSD Treatment Beyond MDMA appeared first on MedCity News.
